Changes in vital signs during adrenaline administration for hemostasis in intracordal injection: an observational study with a hypothetical design of endotracheal adrenaline administration in cardiopulmonary arrest

• Published in: Journal of cardiothoracic surgery Vol. 18; no. 1; pp. 1 - 8
• Main Authors: Hasegawa, Tomohiro, Watanabe, Yusuke
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 06.10.2023; BioMed Central; BMC
• Subjects: Advanced cardiovascular life support; Airway management; Anesthesia; Basic fibroblast growth factor; Blood circulation; Blood pressure; Cardiopulmonary arrest; Drug dosages; Endotracheal adrenaline administration; Epiglottis; Epinephrine; Ethical aspects; Ethics; Heart beat; Heart rate; Hemostasis; Hemostatics; Human subjects; Injection; Intracordal injection under local anesthesia; Intravenous administration; Larynx; Local anesthesia; Medical records; Observational studies; Otolaryngology; Patients; Phenols; Standard deviation; Trachea; Vital signs; Vocal organs; Japan
• ISSN: 1749-8090; 1749-8090
• DOI: 10.1186/s13019-023-02376-1

Background The background is that intravenous adrenaline administration is recommended for advanced cardiovascular life support in adults and endotracheal administration is given low priority. The reason is that the optimal dose of adrenaline in endotracheal administration is unknown, and it is ethically difficult to design studies of endotracheal adrenaline administration with non-cardiopulmonary arrest. We otolaryngologists think so because we administered adrenaline to the vocal folds for hemostasis after intracordal injection under local anesthesia, but have had few cases of vital changes. We hypothesized that examining vital signs before and after adrenaline administration for hemostasis would help determine the optimal dose of endotracheal adrenaline. Methods We retrospectively examined the medical records of 79 patients who visited our hospital from January 2018 to December 2020 and received adrenaline in the vocal folds and trachea for hemostasis by intracordal injection under local anesthesia to investigate changes in heart rate and systolic blood pressure before and after the injection. Results The mean heart rates before and after injection were 83.96 [+ or -] 18.51 (standard deviation) beats per minute (bpm) and 81.50 [+ or -] 15.38 (standard deviation) bpm, respectively. The mean systolic blood pressure before and after the injection were 138.13 [+ or -] 25.33 (standard deviation) mmHg and 135.72 [+ or -] 22.19 (standard deviation) mmHg, respectively. Heart rate and systolic blood pressure had P-values of 0.136, and 0.450, respectively, indicating no significant differences. Conclusions Although this study was an observational, changes in vital signs were investigated assuming endotracheal adrenaline administration. The current recommended dose of adrenaline in endotracheal administration with cardiopulmonary arrest may not be effective. In some cases of cardiopulmonary arrest, intravenous and intraosseous routes of adrenaline administration may be difficult and the opportunity for resuscitation may be missed. Therefore, it is desirable to have many options for adrenaline administration. Therefore, if the optimal dose and efficacy of endotracheal adrenaline administration can be clarified, early adrenaline administration will be possible, which will improve return of spontaneous circulation (ROSC) and survival discharge rates. Keywords: Advanced cardiovascular life support, Basic fibroblast growth factor, Cardiopulmonary arrest, Endotracheal adrenaline administration, Intracordal injection under local anesthesia